Skin Cancer: Types, Warning Signs, and Early Detection

Skin cancer is the most commonly diagnosed cancer in the United States, with the American Cancer Society estimating over 5 million cases of non-melanoma skin cancer treated annually. This page covers the three primary malignant types — basal cell carcinoma, squamous cell carcinoma, and melanoma — along with the biological mechanisms that drive their development, the clinical warning signs used for early identification, and the classification frameworks that dermatologists and pathologists use to distinguish between them. Understanding these distinctions matters because survival rates diverge sharply depending on the stage and type at the time of diagnosis.

• Definition and scope
• Core mechanics or structure
• Causal relationships or drivers
• Classification boundaries
• Tradeoffs and tensions
• Common misconceptions
• Detection checklist
• Reference table or matrix

Definition and scope

Skin cancer describes the uncontrolled proliferation of abnormal cells originating in the skin, the body's largest organ. The three clinically and histologically distinct categories — basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma — differ in cell of origin, metastatic potential, and clinical behavior. A fourth category, Merkel cell carcinoma, represents a rare neuroendocrine malignancy of the skin that carries a significantly higher mortality rate than BCC or SCC.

The National Cancer Institute classifies skin cancers broadly as either keratinocyte carcinomas (BCC and SCC, collectively referred to as non-melanoma skin cancers) or melanocytic tumors (melanoma and its variants). This taxonomic separation is clinically significant: keratinocyte carcinomas rarely metastasize when caught early, while melanoma carries a five-year survival rate of approximately 99% for localized disease but drops to 32% for distant-stage disease, according to Surveillance, Epidemiology, and End Results (SEER) Program data from the National Cancer Institute.

For a broader orientation to skin conditions within the dermatology landscape, the skin conditions overview provides foundational context. The regulatory context for dermatology details how skin cancer screening and treatment guidelines intersect with federal and state oversight frameworks.

Core mechanics or structure

All three primary skin cancers originate from distinct cell populations within the skin's layered architecture. The epidermis — the outermost layer — contains three cell types relevant to malignant transformation:

• Keratinocytes in the basal and squamous layers give rise to BCC and SCC respectively.
• Melanocytes, which produce melanin in the stratum basale, are the origin cells for melanoma.
• Merkel cells, mechanoreceptive cells near the basal layer, are the origin of Merkel cell carcinoma.

In BCC, mutations in the hedgehog signaling pathway — specifically in the PTCH1 tumor suppressor gene — are the central molecular driver. Ultraviolet (UV) radiation induces C→T and CC→TT nucleotide transitions, a mutational signature that the National Institute of Environmental Health Sciences (NIEHS) has identified as characteristic of UV-induced DNA damage.

In SCC, the TP53 tumor suppressor gene is mutated in approximately 50% of cases, with UV-specific signature mutations again predominating. SCC typically evolves through a precancerous stage — actinic keratosis — before progressing to in situ or invasive carcinoma.

Melanoma's molecular landscape is more heterogeneous. BRAF mutations, present in approximately 50% of cutaneous melanomas according to the American Cancer Society, are among the most therapeutically targetable alterations. NRAS mutations account for roughly 20% of cases, while NF1 and wild-type melanomas constitute the remainder.

For detail on how dermatologists image and evaluate suspicious lesions at the cellular level, dermoscopy and skin imaging covers the optical and digital techniques involved.

Causal relationships or drivers

UV radiation from both solar and artificial sources is the primary environmental driver across all three keratinocyte carcinomas and most cutaneous melanomas. The International Agency for Research on Cancer (IARC), a unit of the World Health Organization, classifies UV radiation as a Group 1 carcinogen — meaning there is sufficient evidence of carcinogenicity in humans.

The specific drivers break down as follows:

Chronic cumulative UV exposure — accumulated over decades — is the dominant driver of BCC and SCC. Outdoor workers, individuals in high-altitude environments, and those living at lower latitudes accumulate significantly higher UV doses over a lifetime. The Occupational Safety and Health Administration (OSHA) recognizes solar ultraviolet radiation as an occupational hazard, relevant to occupational skin conditions more broadly.

Intermittent intense UV exposure — particularly blistering sunburns occurring before age 18 — is more strongly correlated with melanoma risk than cumulative exposure, according to the American Academy of Dermatology (AAD).

Tanning bed use increases melanoma risk by 75% when first used before age 35, according to data cited by the International Agency for Research on Cancer (IARC) Monograph 100D. The U.S. Food and Drug Administration (FDA) reclassified ultraviolet lamps used in sunlamps and tanning beds as Class II medical devices requiring special controls in 2014, a regulatory action catalogued in FDA's final rule (79 FR 71793).

Additional causal drivers include:
- Immunosuppression (organ transplant recipients face an 80-fold increased risk of SCC relative to the general population, per published transplant dermatology literature)
- Exposure to arsenic, polycyclic aromatic hydrocarbons, or ionizing radiation
- Human papillomavirus (HPV) infection, particularly for SCC on non-sun-exposed sites
- Genetic syndromes including xeroderma pigmentosum, Gorlin syndrome, and familial atypical mole-melanoma (FAMM) syndrome

Classification boundaries

Skin cancer classification operates at three levels: histological type, stage, and risk category.

Histological type determines the cellular origin and baseline behavior. BCC is locally invasive but metastasizes in fewer than 0.1% of cases. SCC metastasizes in approximately 2–5% of cases overall, but in high-risk anatomical locations (ear, lip, non-healing wound) that rate rises to 10–30%. Melanoma's metastatic potential is stage-dependent but substantially higher than either keratinocyte carcinoma.

Staging follows the American Joint Committee on Cancer (AJCC) TNM system, with the 8th edition (2017) establishing separate staging protocols for cutaneous melanoma, Merkel cell carcinoma, and cutaneous SCC of the head and neck. BCC lacks a formal AJCC TNM stage due to its low metastatic potential, though high-risk features are codified in clinical guidelines.

Risk stratification for SCC, as defined by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, separates tumors into low-risk and high-risk categories based on tumor diameter, depth of invasion, location, perineural invasion, degree of differentiation, and immunosuppression status.

Melanoma subtyping includes:
- Superficial spreading melanoma (~70% of cases)
- Nodular melanoma (~15–30% of cases; most aggressive growth pattern)
- Lentigo maligna melanoma (~4–15%; associated with chronic sun-damaged skin)
- Acral lentiginous melanoma (~2–3% of cases in white populations; higher proportion in skin of color populations — see dermatology and skin of color)

Tradeoffs and tensions

Overdiagnosis versus underdetection is a documented tension in skin cancer screening policy. The U.S. Preventive Services Task Force (USPSTF), as of its 2023 review, found insufficient evidence to recommend routine full-body skin examination by a clinician for asymptomatic adults, citing concerns about overdiagnosis and the harms of unnecessary biopsies. The AAD, by contrast, advocates for annual full-body skin examinations, particularly in high-risk populations. This divergence in recommendations from two authoritative bodies reflects genuine uncertainty in the screening evidence base, not simple disagreement.

Biopsy interpretation variability presents another challenge. A study published in the JAMA Dermatology by Elmore et al. found that pathologists disagreed on the classification of melanocytic lesions — particularly the category of "moderately dysplastic nevus" — at clinically meaningful rates, illustrating that classification boundaries are not always crisp in practice.

Treatment selection for BCC and SCC involves tradeoffs between functional preservation and oncological completeness. Mohs surgery achieves the highest reported cure rates (99% for primary BCC, 97% for primary SCC) through staged excision with immediate margin analysis, but requires specialized training and is more resource-intensive than standard excision.

Common misconceptions

Misconception: Skin cancer only affects fair-skinned individuals.
Melanoma and SCC do occur at significantly lower rates in individuals with darker skin phototypes, but they are not absent. In Black patients, acral lentiginous melanoma — occurring on palms, soles, and under nails — is disproportionately represented and is frequently diagnosed at a later stage. The AAD has published specific guidance acknowledging this disparity. Later-stage diagnosis, not absence of disease, accounts for the clinical pattern.

Misconception: A tan is a sign of health.
A tan represents the skin's response to UV-induced DNA damage, not a protective adaptation. Melanin production increases after keratinocyte damage, offering limited additional protection — estimated at a sun protection factor (SPF) of approximately 2 to 4 — while the underlying DNA damage accumulates.

Misconception: Only moles become melanoma.
Approximately 20–30% of melanomas arise within pre-existing nevi (moles), while the majority arise on apparently normal skin, according to data from the American Cancer Society. Relying solely on mole surveillance misses the majority of melanoma presentations.

Misconception: BCC is "just skin cancer" and always minor.
While BCC rarely metastasizes, locally advanced or neglected BCC can cause significant tissue destruction, including invasion of the eye, ear, nose, and in rare cases, bone or skull. Gorlin syndrome (nevoid BCC syndrome) involves PTCH1 germline mutations and produces dozens to hundreds of BCCs over a patient's lifetime.

Detection checklist

The following represents the ABCDE criteria and supplementary warning signs as published by the American Academy of Dermatology (AAD). This checklist is a structured reference framework, not a diagnostic protocol.

ABCDE criteria for melanoma:
- A — Asymmetry: One half of the lesion does not mirror the other
- B — Border: Edges are irregular, ragged, notched, or blurred
- C — Color: Variation within a single lesion — shades of brown, black, red, white, or blue
- D — Diameter: Lesion greater than 6 millimeters (approximately the size of a pencil eraser), though melanomas can be smaller
- E — Evolution: Any change in size, shape, color, or new symptom (bleeding, itching, crusting)

Additional warning signs for BCC and SCC:
- A pearly or waxy bump, often with visible blood vessels, on the face, ear, or neck (BCC)
- A flat, flesh-colored or brown scar-like lesion (morpheaform BCC)
- A firm, red nodule, or a flat lesion with a scaly, crusted surface (SCC)
- An open sore that bleeds, oozes, or crusts and fails to heal within 3 weeks
- A wart-like growth that crusts or bleeds
- A pink growth with raised edges and a crusted center

For acral lentiginous melanoma (non-sun-exposed sites):
- A dark streak under a nail (subungual melanoma), particularly if accompanied by pigment spreading to the surrounding skin (Hutchinson's sign)
- An unusual pigmented lesion on a palm or sole

See skin cancer screening guidelines and sun protection and UV exposure for context on prevention and screening frequency guidance from major health bodies.

Reference table or matrix

For information on how biopsies confirm these diagnoses histologically, see skin biopsy: what to expect. Patients navigating treatment decisions should review patient rights in dermatology care for context on informed consent and second-opinion standards. The home page provides a navigational overview of all dermatology topics covered across this reference.

References

• American Cancer Society — What Is Melanoma Skin Cancer?
• American Academy of Dermatology — ABCDEs of Melanoma
• National Cancer Institute — Skin Cancer
• NCI SEER Program — Melanoma of the Skin Statistics
• [U.S. Preventive Services Task Force — Skin Cancer Screening Recommendation

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)